Go Deep
Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 8,210 | -0.5 | 33.39 | 0.00 | 269.94 |
| Oct 2026 | 9,683 | -0.4 | 30.81 | 0.00 | 249.10 |
| Oct 2026 | 9,013 | -0.4 | 31.98 | 0.00 | 258.85 |
| Oct 2026 | 7,473 | -0.5 | 34.68 | 0.00 | 280.66 |
| Oct 2026 | 6,133 | -0.5 | 37.02 | 0.00 | 298.88 |
| Oct 2026 | 6,835 | -0.5 | 35.03 | 0.00 | 282.23 |
Indaptus Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -1,794,863.0 | -2,541,070.0 | -8,112,450.0 | -2,975,117.0 |
| EPS | -0.0 | -0.2 | — | -3.0 |
Indaptus Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -20,848,916.0 | -15,022,027.0 | -15,423,471.0 | -14,322,798.0 | — |
| EPS | -21.6 | -45.1 | -51.2 | -48.4 | — |
Indaptus Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 9,310,168.0 | 7,338,756.0 | 14,923,878.0 | 28,063,806.0 | — |
| Total Liabilities | 6,158,575.0 | 3,393,881.0 | 2,847,380.0 | 3,433,341.0 | — |
| Total Equity | 3,151,593.0 | 3,944,875.0 | 12,076,498.0 | 24,630,465.0 | — |
Owes vs Owns
Indaptus Therapeutics, Inc. owed $0.05 for every $1 it owned in Jun 2026, down from $0.12 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.05× | 0.66× | 0.46× | 0.19× | 0.12× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Indaptus Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 91.4%Other assets 8.6%
How it's funded — Dec 2025
Payables 5.8%Other liabilities 60.3%Shareholders' equity 33.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 8.5 | 5.8 | 13.4 | 26.4 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.1 | 0.2 | 0.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.8 | 1.5 | 1.4 | 1.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.1 | 0.1 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.1 | 0.0 |
| Payables | 0.5 | 0.9 | 0.8 | 1.4 |
| Other liabilities | 5.6 | 2.4 | 1.9 | 2.0 |
| Shareholders' equity | 3.2 | 3.9 | 12.1 | 24.6 |
| Net tangible assets | 3.2 | 3.9 | 12.1 | 24.6 |
Indaptus Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -14,823,256.0 | -12,323,188.0 | -13,405,315.0 | -13,078,347.0 | — |
| Investing Activities | — | 0.0 | 17,140,568.0 | -16,427,018.0 | 447,746.0 |
| Financing Activities | 17,544,131.0 | 4,747,888.0 | 0.0 | 0.0 | — |